APA-话题@MedSci

#APA#

153篇内容 | 3635人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338236, encodeId=904c1338236cd, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, objectType=article, longId=219105, objectId=f9f621910501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9f621910501, replyNumber=0, likeNumber=62, createdTime=2021-10-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9f621910501, moduleTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9f621910501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338235, encodeId=7b2a1338235f5, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, objectType=article, longId=213648, objectId=33d021364893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33d021364893, replyNumber=0, likeNumber=72, createdTime=2021-07-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33d021364893, moduleTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33d021364893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338234, encodeId=d4171338234b1, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , objectType=article, longId=213257, objectId=9d5921325e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5921325e93, replyNumber=0, likeNumber=65, createdTime=2021-06-27, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5921325e93, moduleTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d5921325e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338232, encodeId=7b86133823269, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数, objectType=article, longId=208933, objectId=66cb208933a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cb208933a5, replyNumber=0, likeNumber=78, createdTime=2021-03-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cb208933a5, moduleTitle=Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cb208933a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338231, encodeId=a29d13382314b, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=指南解读：2021 APASL共识指南：药物性肝损伤, objectType=article, longId=208530, objectId=cd5420853058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd5420853058, replyNumber=0, likeNumber=70, createdTime=2021-03-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd5420853058, moduleTitle=指南解读：2021 APASL共识指南：药物性肝损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd5420853058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338230, encodeId=4f8713382309a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, objectType=article, longId=207230, objectId=677220e230b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677220e230b0, replyNumber=0, likeNumber=83, createdTime=2021-02-19, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677220e230b0, moduleTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=677220e230b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338229, encodeId=212a133822959, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, objectType=article, longId=206440, objectId=319320644031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=319320644031, replyNumber=0, likeNumber=76, createdTime=2021-02-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=319320644031, moduleTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=319320644031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338228, encodeId=84c11338228ae, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=复发性卵巢癌：Rucaparib 维持治疗优势分析, objectType=article, longId=206094, objectId=3892206094de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3892206094de, replyNumber=0, likeNumber=72, createdTime=2021-01-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3892206094de, moduleTitle=复发性卵巢癌：Rucaparib 维持治疗优势分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3892206094de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338227, encodeId=bd48133822ef7, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响, objectType=article, longId=205644, objectId=d7f2205644a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7f2205644a9, replyNumber=0, likeNumber=58, createdTime=2021-01-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7f2205644a9, moduleTitle=Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7f2205644a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338226, encodeId=4610133822627, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, objectType=article, longId=202282, objectId=8ace202282a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ace202282a7, replyNumber=0, likeNumber=0, createdTime=2020-10-21, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ace202282a7, moduleTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ace202282a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338225, encodeId=2d6e1338225b7, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, objectType=article, longId=201506, objectId=3857201506d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3857201506d7, replyNumber=0, likeNumber=75, createdTime=2020-10-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3857201506d7, moduleTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3857201506d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338224, encodeId=5429133822498, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, objectType=article, longId=201242, objectId=0c6d2012422b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6d2012422b, replyNumber=0, likeNumber=0, createdTime=2020-09-27, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6d2012422b, moduleTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6d2012422b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338223, encodeId=c812133822335, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Br J Cancer：sapanisertib治疗晚期实体瘤, objectType=article, longId=200713, objectId=ae62200e1330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae62200e1330, replyNumber=0, likeNumber=96, createdTime=2020-09-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae62200e1330, moduleTitle=Br J Cancer：sapanisertib治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae62200e1330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338222, encodeId=510313382221d, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ESC 2020：DAPA-CKD研究：达格列净在慢性肾功能不全患者中的应用, objectType=article, longId=200211, objectId=ae5720021115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae5720021115, replyNumber=0, likeNumber=80, createdTime=2020-09-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae5720021115, moduleTitle=ESC 2020：DAPA-CKD研究：达格列净在慢性肾功能不全患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae5720021115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338221, encodeId=02c3133822128, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, objectType=article, longId=198399, objectId=7f8819839938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8819839938, replyNumber=0, likeNumber=68, createdTime=2020-08-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8819839938, moduleTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8819839938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338220, encodeId=302913382206d, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, objectType=article, longId=197123, objectId=dc3519e123a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3519e123a3, replyNumber=0, likeNumber=68, createdTime=2020-07-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3519e123a3, moduleTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc3519e123a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338219, encodeId=74f713382196c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血, objectType=article, longId=196108, objectId=e997196108f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e997196108f4, replyNumber=0, likeNumber=88, createdTime=2020-06-20, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e997196108f4, moduleTitle=WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e997196108f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338218, encodeId=fa2513382188c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Clin J Am Soc Nephrol：Dapagliflozin对糖尿病肾病患者磷酸盐调节激素的影响, objectType=article, longId=195991, objectId=abfe195991ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abfe195991ed, replyNumber=0, likeNumber=67, createdTime=2020-06-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abfe195991ed, moduleTitle=Clin J Am Soc Nephrol：Dapagliflozin对糖尿病肾病患者磷酸盐调节激素的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abfe195991ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338217, encodeId=84ff133821ed1, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, objectType=article, longId=195598, objectId=203c1955983f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203c1955983f, replyNumber=0, likeNumber=52, createdTime=2020-06-11, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203c1955983f, moduleTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203c1955983f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338216, encodeId=1e211338216da, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性, objectType=article, longId=195113, objectId=8ff319511304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ff319511304, replyNumber=0, likeNumber=82, createdTime=2020-06-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ff319511304, moduleTitle=基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ff319511304)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性

2021-10-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请

2021-07-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系

2021-06-27

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数

2021-03-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

指南解读：2021 APASL共识指南：药物性肝损伤

2021-03-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）

2021-02-19

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见

2021-02-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

复发性卵巢癌：Rucaparib 维持治疗优势分析

2021-01-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响

2021-01-13

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效

2020-10-21

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Xevinapant治疗头颈癌：步入大型III期临床试验

2020-10-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究

2020-09-27

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Br J Cancer：sapanisertib治疗晚期实体瘤

2020-09-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ESC 2020：DAPA-CKD研究：达格列净在慢性肾功能不全患者中的应用

2020-09-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

达格列净III期DAPA-CKD试验达到所有主要终点和次要终点

2020-08-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好

2020-07-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血

2020-06-20

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Clin J Am Soc Nephrol：Dapagliflozin对糖尿病肾病患者磷酸盐调节激素的影响

2020-06-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

2020-06-11

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性

2020-06-03

科室
- - 订阅+
  - 更多科室
工具
服务